Nucleostemin affects the proliferation but not differentiation of oral squamous cell carcinoma cells

Cancer Science

Volumn 102, Issue 7, 2011, Pages 1418-1423

  Yoshida, Ryoji ^a   Fujimoto, Tetsuhiro ^a   Kudoh, Shinji ^a   Nagata, Masashi ^a   Nakayama, Hideki ^a   Shinohara, Masanori ^a   Ito, Takaaki ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 1B; CYTOKERATIN 19; INVOLUCRIN; KI 67 ANTIGEN; NUCLEOLIN; NUCLEOSTEMIN; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ARTICLE; CELL DIFFERENTIATION; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN TISSUE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA; TONGUE CARCINOMA;

CALCIUM; CARCINOMA, SQUAMOUS CELL; CELL DIFFERENTIATION; CELL LINE, TUMOR; CELL PROLIFERATION; GTP-BINDING PROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; KERATIN-19; KI-67 ANTIGEN; MOUTH NEOPLASMS; NUCLEAR PROTEINS; RNA, MESSENGER; RNA, SMALL INTERFERING;

EID: 79959197140     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2011.01935.x     Document Type: Article

References (64)

1. Petersen PE. The world oral health report 2003: continuous improvement of oral health in the 21st century - the approach of the WHO global oral health programme. Community Dent Oral Epidemiol 2003; 31 (Suppl 1): 3-23.
2. Jemal A, Siegel R, Ward E et al. Cancer statistics, 2006. CA Cancer J Clin 2006; 56: 106-30.
3. Forastiere AA, Goepfert H, Maor M et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med 2003; 349: 2091-8.
4. Napier SS, Speight PM. Natural history of potentially malignant oral lesions and conditions: an overview of the literature. J Oral Pathol Med 2008; 37: 1-10.
5. Barnes L, Eveson JW, Reichart P, Sidransky D. Pathology and Genetics of Head and Neck Tumours. Lyon: IARC, 2005; 177-80.
6. Warnakulasuriya S, Reibel J, Bouquot J, Dabelsteen E. Oral epithelial dysplasia classification systems: predictive value, utility, weaknesses and scope for improvement. J Oral Pathol Med 2008; 37: 127-33.
7. Warnakulasuriya S. Histological grading of oral epithelial dysplasia: revisited. J Pathol 2001; 194: 294-7.
8. Tsai RY, McKay RD. A nucleolar mechanism controlling cell proliferation in stem cells and cancer cells. Genes Dev 2002; 16: 2991-3003.
9. Baddoo M, Hill K, Wilkinson R et al. Characterization of mesenchymal stem cells isolated from murine bone marrow by negative selection. J Cell Biochem 2003; 89: 1235-49.
10. Liu SJ, Cai ZW, Liu YJ et al. Role of nucleostemin in growth regulation of gastric cancer, liver cancer and other malignancies. World J Gastroenterol 2004; 10: 1246-9.
11. Lacina L, Smetana K Jr, Dvorankova B, Stork J, Plzakova Z, Gabius HJ. Immunocyto- and histochemical profiling of nucleostemin expression: marker of epidermal stem cells? J Dermatol Sci 2006; 44: 73-80.
12. Yaghoobi MM, Mowla SJ, Tiraihi T. Nucleostemin, a coordinator of self-renewal, is expressed in rat marrow stromal cells and turns off after induction of neural differentiation. Neurosci Lett 2005; 390: 81-6.
13. Cada Z, Boucek J, Dvorankova B et al. Nucleostemin expression in squamous cell carcinoma of the head and neck. Anticancer Res 2007; 27: 3279-84.
14. Jafarnejad SM, Mowla SJ, Matin MM. Knocking-down the expression of nucleostemin significantly decreases rate of proliferation of rat bone marrow stromal stem cells in an apparently p53-independent manner. Cell Prolif 2008; 41: 28-35.
15. Ma H, Pederson T. Depletion of the nucleolar protein nucleostemin causes G1 cell cycle arrest via the p53 pathway. Mol Biol Cell 2007; 18: 2630-5.
16. Ma H, Pederson T. Nucleostemin: a multiplex regulator of cell-cycle progression. Trends Cell Biol 2008; 18: 575-9.
17. Tsai RY, McKay RD. A multistep, GTP-driven mechanism controlling the dynamic cycling of nucleostemin. J Cell Biol 2005; 168: 179-84.
18. Nikpour P, Mowla SJ, Jafarnejad SM, Fischer U, Schulz WA. Differential effects of nucleostemin suppression on cell cycle arrest and apoptosis in the bladder cancer cell lines 5637 and SW1710. Cell Prolif 2009; 42: 762-9.
19. Sijin L, Ziwei C, Yajun L et al. The effect of knocking-down nucleostemin gene expression on the in vitro proliferation and in vivo tumorigenesis of HeLa cells. J Exp Clin Cancer Res 2004; 23: 529-38.
20. Beekman C, Nichane M, De Clercq S et al. Evolutionarily conserved role of nucleostemin: controlling proliferation of stem/progenitor cells during early vertebrate development. Mol Cell Biol 2006; 26: 9291-301.
21. Liu RL, Zhang ZH, Zhao WM et al. Expression of nucleostemin in prostate cancer and its effect on the proliferation of PC-3 cells. Chin Med J (Engl) 2008; 121: 299-304.
22. Dai MS, Sun XX, Lu H. Aberrant expression of nucleostemin activates p53 and induces cell cycle arrest via inhibition of MDM2. Mol Cell Biol 2008; 28: 4365-76.
23. Siddiqi S, Gude N, Hosoda T et al. Myocardial induction of nucleostemin in response to postnatal growth and pathological challenge. Circ Res 2008; 103: 89-97.
24. Fan Y, Liu Z, Zhao S et al. Nucleostemin mRNA is expressed in both normal and malignant renal tissues. Br J Cancer 2006; 94: 1658-62.
25. Tjwa M, Dimmeler S. A nucleolar weapon in our fight for regenerating adult hearts: nucleostemin and cardiac stem cells. Circ Res 2008; 103: 4-6.
26. Crissman JD, Visscher DW, Sakr W. Premalignant lesions of the upper aerodigestive tract: pathologic classification. J Cell Biochem Suppl 1993; 17F: 49-56.
27. Ohnishi K, Ota I, Takahashi A, Ohnishi T. Glycerol restores p53-dependent radiosensitivity of human head and neck cancer cells bearing mutant p53. Br J Cancer 2000; 83: 1735-9.
28. Imai Y, Ohnishi K, Yasumoto J et al. Glycerol enhances radiosensitivity in a human oral squamous cell carcinoma cell line (Ca9-22) bearing a mutant p53 gene via Bax-mediated induction of apoptosis. Oral Oncol 2005; 41: 631-6.
29. Rheinwald JG, Green H. Formation of a keratinizing epithelium in culture by a cloned cell line derived from a teratoma. Cell 1975; 6: 317-30.
30. Rheinwald JG, Green H. Serial cultivation of strains of human epidermal keratinocytes: the formation of keratinizing colonies from single cells. Cell 1975; 6: 331-43.
31. Hudson DL, Weiland KL, Dooley TP, Simon M, Watt FM. Characterisation of eight monoclonal antibodies to involucrin. Hybridoma 1992; 11: 367-79.
32. Banks-Schlegel S, Green H. Involucrin synthesis and tissue assembly by keratinocytes in natural and cultured human epithelia. J Cell Biol 1981; 90: 732-7.
33. Sumitomo S, Kumasa S, Iwai Y, Mori M. Involucrin expression in epithelial tumors of oral and pharyngeal mucosa and skin. Oral Surg Oral Med Oral Pathol 1986; 62: 155-63.
34. Arany I, Adler-Storthz K, Chen Z, Tyring SK, Brysk H, Brysk MM. Differentiation markers in oral carcinoma cell lines and tumors. Anticancer Res 1997; 17: 4607-10.
35. Krishna S, Brown N, Faller DV, Spanjaard RA. Differential effects of short-chain fatty acids on head and neck squamous carcinoma cells. Laryngoscope 2002; 112: 645-50.
36. Nakayama H, Ikebe T, Shirasuna K. Effects of IkappaB kinase alpha on the differentiation of squamous carcinoma cells. Oral Oncol 2005; 41: 729-37.
37. Lindberg K, Rheinwald JG. Suprabasal 40 kd keratin (K19) expression as an immunohistologic marker of premalignancy in oral epithelium. Am J Pathol 1989; 134: 89-98.
38. Tu CL, Oda Y, Komuves L, Bikle DD. The role of the calcium-sensing receptor in epidermal differentiation. Cell Calcium 2004; 35: 265-73.
39. Pillai S, Bikle DD, Mancianti ML, Hincenbergs M. Uncoupling of the calcium-sensing mechanism and differentiation in squamous carcinoma cell lines. Exp Cell Res 1991; 192: 567-73.
40. Hoffman HT, Subnani M, Cha M et al. Calcium regulation of antigen expression on normal and malignant human squamous cells in vitro. Arch Otolaryngol Head Neck Surg 1990; 116: 299-303.
41. Rosby R, Cui Z, Rogers E, deLivron MA, Robinson VL, DiMario PJ. Knockdown of the Drosophila GTPase nucleostemin 1 impairs large ribosomal subunit biogenesis, cell growth, and midgut precursor cell maintenance. Mol Biol Cell 2009; 20: 4424-34.
42. Romanova L, Grand A, Zhang L et al. Critical role of nucleostemin in pre-rRNA processing. J Biol Chem 2009; 284: 4968-77.
43. Kudron MM, Reinke V. C. elegans nucleostemin is required for larval growth and germline stem cell division. PLoS Genet 2008; 4: e1000181.
44. Hirai H, Romanova L, Kellner S et al. Post-mitotic role of nucleostemin as a promoter of skeletal muscle cell differentiation. Biochem Biophys Res Commun 2009; 391: 299-304.
45. Kautsky MB, Fleckman P, Dale BA. Retinoic acid regulates oral epithelial differentiation by two mechanisms. J Invest Dermatol 1995; 104: 546-53.
46. Tomakidi P, Fusenig NE, Kohl A, Komposch G. Histomorphological and biochemical differentiation capacity in organotypic co-cultures of primary gingival cells. J Periodontal Res 1997; 32: 388-400.
47. Kautsky MB, Fleckman P, Dale BA. Retinoic acid regulates oral epithelial differentiation by two mechanisms. J Invest Dermatol 1995; 104: 224-30.
48. Bernardi R, Pandolfi PP. The nucleolus: at the stem of immortality. Nat Med 2003; 9: 24-5.
49. Deng C, Zhang P, Harper JW, Elledge SJ, Leder P. Mice lacking p21CIP1/WAF1 undergo normal development, but are defective in G1 checkpoint control. Cell 1995; 82: 675-84.
50. Gartel AL, Radhakrishnan SK. Lost in transcription: p21 repression, mechanisms, and consequences. Cancer Res 2005; 65: 3980-5.
51. Toyoshima H, Hunter T. p27, a novel inhibitor of G1 cyclin-Cdk protein kinase activity, is related to p21. Cell 1994; 78: 67-74.
52. Polyak K, Kato JY, Solomon MJ et al. p27Kip1, a cyclin-Cdk inhibitor, links transforming growth factor-beta and contact inhibition to cell cycle arrest. Genes Dev 1994; 8: 9-22.
53. Polyak K, Lee MH, Erdjument-Bromage H et al. Cloning of p27Kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell 1994; 78: 59-66.
54. Harper JW, Adami GR, Wei N, Keyomarsi K, Elledge SJ. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 1993; 75: 805-16.
55. Xiong Y, Hannon GJ, Zhang H, Casso D, Kobayashi R, Beach D. p21 is a universal inhibitor of cyclin kinases. Nature 1993; 366: 701-4.
56. Bloom J, Pagano M. Deregulated degradation of the cdk inhibitor p27 and malignant transformation. Semin Cancer Biol 2003; 13: 41-7.
57. Fillies T, Woltering M, Brandt B et al. Cell cycle regulating proteins p21 and p27 in prognosis of oral squamous cell carcinomas. Oncol Rep 2007; 17: 355-9.
58. Shintani S, Li C, Mihara M, Hino S, Nakashiro K, Hamakawa H. Skp2 and Jab1 expression are associated with inverse expression of p27(KIP1) and poor prognosis in oral squamous cell carcinomas. Oncology 2003; 65: 355-62.
59. Kudo Y, Takata T, Ogawa I et al. p27Kip1 accumulation by inhibition of proteasome function induces apoptosis in oral squamous cell carcinoma cells. Clin Cancer Res 2000; 6: 916-23.
60. Tamase A, Muraguchi T, Naka K et al. Identification of tumor-initiating cells in a highly aggressive brain tumor using promoter activity of nucleostemin. Proc Natl Acad Sci U S A 2009; 106: 17163-8.
61. Nomura J, Maruyama M, Katano M et al. Differential requirement for nucleostemin in embryonic stem cell and neural stem cell viability. Stem Cells 2009; 27: 1066-76.
62. Kawashima M, Kawakita T, Yoshida S, Shimmura S, Tsubota K. Nucleostemin as a possible progenitor marker of corneal epithelial cells. Mol Vis 2009; 15: 1162-8.
63. Prince ME, Sivanandan R, Kaczorowski A et al. Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma. Proc Natl Acad Sci U S A 2007; 104: 973-8.
64. Harper LJ, Piper K, Common J, Fortune F, Mackenzie IC. Stem cell patterns in cell lines derived from head and neck squamous cell carcinoma. J Oral Pathol Med 2007; 36: 594-603.